R Dhananjay Vaidya
Overview
Explore the profile of R Dhananjay Vaidya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
77
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Simpson C, Griffiths M, Yang J, Nies M, Vaidya R, Brandal S, et al.
ERJ Open Res
. 2021 Oct;
7(4.
PMID: 34651041
Currently available noninvasive markers for assessing disease severity and mortality risk in pulmonary arterial hypertension (PAH) are unrelated to fundamental disease biology. Endostatin, an angiostatic peptide known to inhibit pulmonary...
2.
Daly C, Griffiths M, Simpson C, Yang J, Damico R, Vaidya R, et al.
J Am Heart Assoc
. 2021 Oct;
10(20):e021409.
PMID: 34622662
Background Endostatin, an angiogenic inhibitor, is associated with worse pulmonary arterial hypertension (PAH) outcomes in adults and poor lung growth in children. This study sought to assess whether endostatin is...
3.
Chen J, Griffiths M, Yang J, Nies M, Damico R, Simpson C, et al.
J Pediatr
. 2020 Jul;
223:164-169.e1.
PMID: 32711743
Objective: To assess whether circulating interleukin-6 (IL-6) is associated with measures of disease severity and clinical worsening in pediatric pulmonary arterial hypertension (PAH). Study Design: IL-6 was measured by enzyme-linked...
4.
Simpson C, Chen J, Damico R, Hassoun P, Martin L, Yang J, et al.
Eur Respir J
. 2020 Feb;
55(4).
PMID: 32029443
The pro-inflammatory cytokine interleukin (IL)-6 has been associated with outcomes in small pulmonary arterial hypertension (PAH) cohorts composed largely of patients with severe idiopathic PAH (IPAH). It is unclear whether...
5.
Simpson C, Damico R, Hassoun P, Martin L, Yang J, Nies M, et al.
Chest
. 2020 Jan;
157(6):1606-1616.
PMID: 31987881
Background: Three biomarkers, soluble suppression of tumorigenicity 2 (ST2), galectin 3 (Gal3), and N-terminal brain natriuretic peptide prohormone (NT-proBNP), are approved for noninvasive risk assessment in left-sided heart failure, and...